Lupin announced that it has received approval for its Tavaborole Topical Solution, 5%, from the United States Food and Drug Administration, to market a generic equivalent of Kerydin Topical Solution, 5%, of Anacor
Pharmaceuticals, Inc. The product will be manufactured at Lupin's facility in Pithampur, India.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Tavaborole Topical Solution (RLD: Kerydin) had estimated annual sales of USD 76 million in the U.S. (IQVIA MAT December 2020).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
